SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Tove Per Arne) "

Sökning: WFRF:(Tove Per Arne)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Martinez-Martin, Pablo, et al. (författare)
  • EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease
  • 2015
  • Ingår i: Movement Disorders. - : Wiley. - 0885-3185. ; 30:4, s. 510-516
  • Tidskriftsartikel (refereegranskat)abstract
    • Subcutaneous apomorphine infusion (Apo) and intrajejunal levodopa infusion (IJLI) are two treatment options for patients with advanced Parkinson's disease (PD) and refractory motor complications, with varying cost of treatment. There are no multicenter studies comparing the effects of the two strategies. This open-label, prospective, observational, 6-month, multicenter study compared 43 patients on Apo (48.8% males, age 62.3 +/- 10.6 years; disease duration: 14 +/- 4.4 years; median H & Y stage 3; interquartile range [IQR]: 3-4) and 44 on IJLI (56.8% males, age 62.7 +/- 9.1 years; disease duration: 16.1 +/- 6.7 years; median H & Y stage 4; IQR, 3-4). Cohen's effect sizes (0.8 considered as large) were large with both therapies with respect to total motor, nonmotor, and quality-of-life scores. The Non-Motor Symptoms Scale (NMSS) with Apo showed moderate improvement, whereas sleep/fatigue, gastrointestinal, urinary, and sexual dimensions of the NMSS showed significantly higher improvement with IJLI. Seventy-five percent on IJLI improved in their quality-of-life and nonmotor symptoms (NMS), whereas in the Apo group, a similar proportion improved in quality of life, but 40% in NMS. Adverse effects included peritonitis with IJLI and skin nodules on Apo. Based on this open-label, nonrandomized, comparative study, we report that, in advanced Parkinson's patients, both IJLI and Apo infusion therapy appear to provide a robust improvement in motor symptoms, motor complications, quality-of-life, and some NMS. Controlled, randomized studies are required. (c) 2014 International Parkinson and Movement Disorder Society
  •  
2.
  • Exhibition: Space Waves and a Tale : Hannes Alfvén (1908–1995). Nobel Prize laureate in physics 1970.
  • 2022
  • Konstnärligt arbeteabstract
    • The exhibition Space Waves and a Tale presented parts of Alfvén's extensive research, his community engagement and last but not least, his fictional story The tale of the great computing machine from 1966.  In 1970 KTH professor Hannes Alfvén (1908 – 1995) was awarded the Nobel Prize in physics for his discoveries and applications in plasma physics. The exhibition Space Waves and a Tale presented parts of Alfvén's extensive research, his community engagement and his fictional story The tale of the great computing machine from 1966.Alfvén's research allow us to explore all corners of the universe – from the auroras on earth to the auroras on other planets, from solar wind to stellar wind, from plasma phenomena in the laboratory to astrophysical plasma phenomena in ours and other galaxies.The tale of the great computing machine is a satirical tale that tells the story of a future society controlled by computers and is also the source of inspiration for an opera with the same name.As part of the exhibition Space Waves and a Tale visitors were invited to share their visions of how future technology will shape our lives and societies. Two students from the KTH School of Architecture have contributed to the exhibition by designing and building a flexible and sustainable exhibition module. Students from BOOMERANG REXUS participated with objects related to aerospace research.Space Waves and a Tale was produced by the project group for KTH 200 years anniversary celebration together with KTH Library, The Opera: The Tale of the Great Computing Machine, the Division of Space and Plasma Physics and the KTH School of Architecture.In connection with the exhibithion there was a book discussion, popular science lecture and a class visit.
  •  
3.
  •  
4.
  • Pereira, Maria J, 1981-, et al. (författare)
  • FKBP5 expression in human adipose tissue increases following dexamethasone exposure and is associated with insulin resistance
  • 2014
  • Ingår i: Metabolism: Clinical and Experimental. - : Elsevier BV. - 0026-0495 .- 1532-8600. ; 63:9, s. 1198-1208
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective To study effects of dexamethasone on gene expression in human adipose tissue aiming to identify potential novel mechanisms for glucocorticoid-induced insulin resistance. Materials/methods Subcutaneous and omental adipose tissue, obtained from non-diabetic donors (10 M/15 F; age: 28-60 years; BMI: 20.7-30.6 kg/m2), was incubated with or without dexamethasone (0.003-3 μmol/L) for 24 h. Gene expression was assessed by microarray and real time-PCR and protein expression by immunoblotting. Results FKBP5 (FK506-binding protein 5) and CNR1 (cannabinoid receptor 1) were the most responsive genes to dexamethasone in both subcutaneous and omental adipose tissue (~ 7-fold). Dexamethasone increased FKBP5 gene and protein expression in a dose-dependent manner in both depots. The gene product, FKBP51 protein, was 10-fold higher in the omental than in the subcutaneous depot, whereas the mRNA levels were similar. Higher FKBP5 gene expression in omental adipose tissue was associated with reduced insulin effects on glucose uptake in both depots. Furthermore, FKBP5 gene expression in subcutaneous adipose tissue was positively correlated with serum insulin, HOMA-IR and subcutaneous adipocyte diameter and negatively with plasma HDL-cholesterol. FKBP5 SNPs were found to be associated with type 2 diabetes and diabetes-related phenotypes in large population-based samples. Conclusions Dexamethasone exposure promotes expression of FKBP5 in adipose tissue, a gene that may be implicated in glucocorticoid-induced insulin resistance. © 2014 Elsevier Inc.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy